The Canadian Cancer Survivor Network is making a patient evidence submission on Gene Expression Profiling testing to Health Quality Ontario (HQO). HQO is currently conducting a health technology assessment of this test in Ontario for early invasive breast cancer. Regardless of your experience with a Gene Expression Profiling test, such as Oncotype Dx or EndoPredict, your input will help to inform the submission and provide the expert committee at HQO with the patient perspective and values they are looking for as they issue their final funding recommendation for Gene Expression Profiling tests in Ontario.
Please click on the link below to complete the Gene Expression Profiling testing survey by no later than October 14, 2019. If you have any questions about the survey, please contact Filomena at email@example.com or at 416 809 2889.
Please note: patient privacy and confidentiality will be maintained at all times.
Take the survey here: https://connect.impetusdigital.com/gep-ccsn